1. Academic Validation
  2. Elevated FBXL18 promotes RPS15A ubiquitination and SMAD3 activation to drive HCC

Elevated FBXL18 promotes RPS15A ubiquitination and SMAD3 activation to drive HCC

  • Hepatol Commun. 2023 Jun 28;7(7):e00198. doi: 10.1097/HC9.0000000000000198.
Hong-Qiang Yu 1 Feng Li 2 HaoJun Xiong 1 Lei Fang 1 Jie Zhang 1 Ping Bie 2 Chuan-Ming Xie 1
Affiliations

Affiliations

  • 1 Key Laboratory of Hepatobiliary and Pancreatic Surgery, Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, P.R. China.
  • 2 Department of Hepatobiliary Surgery, The Third Affiliated hospital of Chongqing Medical University, Chongqing, P.R. China.
Abstract

Background: F-box and leucine-rich repeat protein 18 (FBXL18) is an E3 ubiquitin ligase that is reported to be involved in the tumorigenesis of various types of Cancer. However, it remains unknown whether FBXL18 is correlated with hepatocarcinogenesis.

Methods and results: In the current study, we found that FBXL18 was highly expressed in HCC tissues and positively associated with poor overall survival of HCC patients. FBXL18 was an independent risk factor for HCC patients. We observed that FBXL18 drove HCC in FBXL18 transgenic mice. Mechanistically, FBXL18 promoted the K63-linked ubiquitination of small-subunit ribosomal protein S15A (RPS15A) and enhanced its stability, increasing Smad Family member 3 (SMAD3) levels and translocation to the nucleus and promoting HCC cell proliferation. Moreover, the knockdown of RPS15A or SMAD3 significantly suppressed FBXL18-mediated HCC proliferation. In clinical samples, elevated FBXL18 expression was positively associated with RPS15A expression.

Conclusion: FBXL18 promotes RPS15A ubiquitination and upregulates SMAD3 expression, leading to hepatocellular carcinogenesis, and this study provides a novel therapeutic strategy for HCC treatment by targeting the FBXL18/RPS15A/SMAD3 pathway.

Figures
Products